Clinical trials: Semaglutide
Alcohol Use Disorder, Cigarette Smoking
Semaglutide for Alcohol Use Disorder
This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol…
- Trial name
- NCT05520775
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects…
- Trial name
- NCT05064735
- Testing
- semaglutide 2.4 mg
- Where
- 122 sites in United States, Canada and 9 more
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Aging
Semaglutide Use in Elderly Obese Patients
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly…
- Trial name
- NCT05302596
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Tobacco Use Disorder, Nicotine Addiction
Effects of Semaglutide on Nicotine Intake
Tobacco use remains the foremost cause of preventable deaths in the U.S. and worldwide. Advancing new smoking cessation therapies, including those targeting novel biological mechanisms, is a critical public health priority.
- Trial name
- NCT05530577
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Healthy Volunteers, Diabetes Mellitus, Type 2
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin).
- Conditions
- Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity
- Trial name
- NCT04189848
- Testing
- Semaglutide, Dulaglutide
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
HIV/AIDS, Lipohypertrophy
Effects of Semaglutide in HIV-Associated Lipohypertrophy
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream…
- Conditions
- HIV/AIDS, Lipohypertrophy, Obesity
- Trial name
- NCT04019197
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Diabetes
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the…
- Trial name
- NCT05768945
- Testing
- Semaglutide, DPP-4 inhibitor
- Where
- United States
- Volunteers
- 742,670 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight
A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
This study in healthy men and women compares the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (sc, under the skin).
- Conditions
- Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
- Trial name
- NCT04007107
- Testing
- Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen)
- Where
- Netherlands
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight
A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity
This study in healthy men and women looks at the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (s.c., under the skin).
- Conditions
- Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
- Trial name
- NCT04143945
- Testing
- Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen)
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S